GLTO News and Press, Galecto Inc. From 06/16/23

2023-06-16 17:39:00 ET Gainers: Kezar Life Sciences ( NASDAQ: KZR ) +6% . Telos Corporation ( TLS ) +4% . Dyne Therapeutics ( DYN ) +4% . Recursion Pharmaceuticals ( RXRX ) +4% . Berry Corporation ( BRY ) +4% . Losers: ...

BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D. will present at the Jefferies ...

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced the last dosing of the last patient in the GALACTIC-1 Phase 2b...

2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...

BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present a poster at the upcoming ATS 2023 Internationa...

2023-04-28 10:09:02 ET Galecto press release ( NASDAQ: GLTO ): Q1 GAAP EPS of -$0.51 beats by $0.12 . Cash, cash equivalents, and investments as of March 31, 2023 were approximately $57.2 million. For further details see: Galecto GAAP EPS of -$0.51 beats by $...

2023-04-18 19:01:14 ET Summary Galecto (GLTO) is a clinical-stage biopharmaceutical company focused on small-molecule antifibrotic and anticancer agents. GLTO has upcoming data readouts in 2023 that could add more evidence to the potential of their therapies, including top-line IP...

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present two posters at the upcoming American Associa...

2023-03-09 09:15:28 ET Galecto press release ( NASDAQ: GLTO ): FY GAAP EPS of -$2.43 beats by $0.08 . Cash, cash equivalents, and investments as of December 31, 2022 were approximately $66.1 million. The Company anticipates that its cash, cash equivalents and inves...

BOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter and year...